Trial reportBMC medicine2026
Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the immunotherapy era, tyrosine kinase inhibitor (TKI) monotherapy is still commonly used for patients with metastatic renal cell carcinoma (RCC) in clinical practice. Prospective evidence on immunotherapy plus tyrosine kinase inhibitor (TKI) after first-line TKI treatment failure is scarce. This study evaluated the efficacy and safety of camrelizumab plus apatinib in this setting.
methodsIn this single-arm, two-center phase 2 study, patients with metastatic clear cell RCC who had failed first-line TKI treatment were enrolled. Camrelizumab 200 mg once every 2 weeks and apatinib 250 mg once daily were continuously administered until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS).
resultsBetween August 2020 and January 2024, 41 patients were enrolled and treated. Median age was 57.0 years (range, 36-81), and 34 (82.9%) patients were males. By the data cutoff date on December 31, 2024, the median follow-up duration was 19.0 months (range, 3.4-49.4). Median PFS was 11.6 months (95% confidence interval [CI], 6.2-18.5), and the median overall survival was not reached. The objective response rate was 41.5% (95% CI, 26.3%-57.9%). The most common grade 3-4 treatment-related adverse events were increased alanine aminotransferase (11 [26.8%]), increased aspartate aminotransferase (nine [22.0%]), and proteinuria (nine [22.0%]). No treatment-related deaths occurred.
conclusionsOur findings suggest the potential of camrelizumab plus apatinib in patients with immunotherapy-naïve metastatic RCC after first-line TKI treatment failure, warranting further investigation.
trial registrationChiCTR.org.cn, ChiCTR2000034384. Registered on July 4, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.